NDS designed for laboratories involved in routine QA and QC testing in the pharmaceutical industry adheres to the requirements of FDA 21 CFR Part 11
Agilent Technologies Europe has announced that shipments of the Agilent Cerity networked data system (NDS) for pharmaceutical QA/QC have begun.
This networked data system is designed for laboratories involved in routine quality assurance (QA) and quality control (QC) testing in the pharmaceutical industry.
The new NDS product adheres to the strict requirements of the US Food and Drug Administration's ruling on electronic records and signatures (FDA 21 CFR Part 11), as well as other regulations and quality standards such as GMP, cGMP, GAMP and ISO 17025.
The system's level-4 instrument control, strong support of the typical workflow, and seamless scalability from standalone, single-user configurations to distributed, multi-user, multi-technique configurations with 100 instrument or more, make this system a perfect fit for pharmaceutical QA/QC labs.
Cerity NDS for Pharmaceutical QA/QC is the second member of the Cerity NDS family to be released, supplementing a dedicated application for chemical QA/QC labs.
The Cerity NDS family provides lab-specific software applications that model the way analysts work in particular laboratory environments, making every step of the lab's workflow more efficient.
The Cerity NDS family is the perfect complement to the Agilent ChemStation family of networked data systems, which provides modular software components for instrument control, data acquisition and data management.
The Agilent Cerity Networked Data System for Pharmaceutical QA/QC is available worldwide and can be ordered through any Agilent Technologies sales office.
Prices vary depending on the network requirements of the laboratory, the number of users, and the number of instruments to be controlled.
